On January 12, 2026, Chengdu Baiyu Pharmaceutical Co., Ltd. received the GMP Certificate (No. M043/25) issued by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.

Chengdu Baiyu Pharmaceuticals Co., Ltd. received a registration certificate for Ginkgolide Injection from the Ministry of Health of Azerbaijan in September 2025.

On January 10, 2025, the registration application for Baiyu Ginkgolide Injection was accepted by the Ministry of Health of Azerbaijan (MOH) and entered the review stage. The product is expected to be approved for marketing before the end of 2025.

Baiyu to receive $70 million upfront, with potential for up to $1.1 billion in development, regulatory and commercial milestones as well as tiered royalties. Unauthorized reproduction is strictly prohibited！